Atara biotherapeutics to participate in the canaccord genuity 43rd annual growth conference

Thousand oaks, calif.--(business wire)---- $atra #cart--atara biotherapeutics, inc. (nasdaq: atra), a leader in t-cell immunotherapy, leveraging its novel allogeneic epstein-barr virus (ebv) t-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that pascal touchon, president and chief executive officer, will participate at the canaccord genuity 43rd annual growth conference on wednesday, august 9, 2023 at 1:00 p.m. pdt / 4:00 p.m. edt. a live webc.
ATRA Ratings Summary
ATRA Quant Ranking